Methods of treating hiv-1 infection utilizing broadly neutralizing human immunodeficiency virus type 1 (hiv-1) gp120-specific monoclonal antibodies
US-2025320281-A1 · Oct 16, 2025 · US
This page is not indexed by search engines while we improve data quality.
Kaminsky Stephen patents
Kaminsky Stephen is listed as an inventor on 27 patents in our database. Major assignees and classification codes are summarized below.
| Metric | Value |
|---|---|
| Inventor | Kaminsky Stephen |
| Total patents | 27 |
| First publication | Sep 15, 2016 |
| Latest publication | Oct 16, 2025 |
Notable patents
Publications ranked by popularity score, then publication date.
Methods of treating HIV-1 infection utilizing broadly neutralizing human immunodeficiency virus type 1 (HIV-1) GP120-specific monoclonal antibodies
US-12410243-B2 · Sep 9, 2025 · US
Monoclonal antibodies directed against trimeric forms of the HIV-1 envelope glycoprotein with broad and potent neutralizing activity
US-12312396-B2 · May 27, 2025 · US
Monoclonal antibodies directed against trimeric forms of the hiv-1 envelope glycoprotein with broad and potent neutralizing activity
US-2024343782-A1 · Oct 17, 2024 · US
Development of a highly efficient second generation fentanyl-conjugate vaccine to treat fentanyl addiction
US-2024307517-A1 · Sep 19, 2024 · US
Monoclonal antibodies directed against trimeric forms of the HIV-1 envelope glycoprotein with broad and potent neutralizing activity
US-12018067-B2 · Jun 25, 2024 · US
Methods of treating hiv-1 infection utilizing broadly neutralizing human immunodeficiency virus type 1 (hiv-1) gp120-specific monoclonal antibodies
US-2024132578-A1 · Apr 25, 2024 · US
Methods of treating HIV-1 infection utilizing broadly neutralizing human immunodeficiency virus type 1 (HIV-1) GP120-specific monoclonal antibodies
US-11845789-B2 · Dec 19, 2023 · US
Monoclonal antibodies directed against trimeric forms of the hiv-1 envelope glycoprotein with broad and potent neutralizing activity
US-2023295278-A1 · Sep 21, 2023 · US
Monoclonal antibodies directed against trimeric forms of the HIV-1 envelope glycoprotein with broad and potent neutralizing activity
US-11584789-B2 · Feb 21, 2023 · US
Recent patents
Latest publications not already listed above.
Methods of treating hiv-1 infection utilizing broadly neutralizing human immunodeficiency virus type 1 (hiv-1) gp120-specific monoclonal antibodies
US-2023027965-A1 · Jan 26, 2023 · US
Adeno-associated virus vector delivery of cystathionine beta-synthase (cbs) enzyme for treating cbs deficiency
US-2022226502-A1 · Jul 21, 2022 · US
Methods of treating HIV-1 infection utilizing broadly neutralizing human immunodeficiency virus type 1 (HIV-1) GP120-specific monoclonal antibodies
US-11319362-B2 · May 3, 2022 · US
Monoclonal antibodies directed against trimeric forms of the hiv-1 envelope glycoprotein with broad and potent neutralizing activity
US-2021040186-A1 · Feb 11, 2021 · US
Monoclonal antibodies directed against trimeric forms of the HIV-1 envelope glycoprotein with broad and potent neutralizing activity
US-10865234-B2 · Dec 15, 2020 · US
Broadly neutralizing human immunodeficiency virus type 1 (HIV-1) GP120-specific monoclonal antibody
US-10836811-B2 · Nov 17, 2020 · US
Broadly neutralizing human immunodeficiency virus type 1 (hiv-1) gp120-specific monoclonal antibody
US-2020024330-A1 · Jan 23, 2020 · US
Monoclonal antibodies directed against trimeric forms of the hiv-1 envelope glycoprotein with broad and potent neutralizing activity
US-2019338017-A1 · Nov 7, 2019 · US
Monoclonal antibodies directed against trimeric forms of the HIV-1 envelope glycoprotein with broad and potent neutralizing activity
US-10407493-B2 · Sep 10, 2019 · US
Monoclonal antibodies directed against trimeric forms of the hiv-1 envelope glycoprotein with broad and potent neutralizing activity
US-2019169273-A1 · Jun 6, 2019 · US
Monoclonal antibodies directed against trimeric forms of the HIV-1 envelope glycoprotein with broad and potent neutralizing activity
US-10239934-B2 · Mar 26, 2019 · US
Monoclonal antibodies directed against trimeric forms of the hiv-1 envelope glycoprotein with broad and potent neutralizing activity
US-2019031742-A1 · Jan 31, 2019 · US
Broadly neutralizing human immunodeficiency virus type 1 (HIV-1) GP120-specific monoclonal antibody
US-10087239-B2 · Oct 2, 2018 · US
Monoclonal antibodies directed against trimeric forms of the HIV-1 envelope glycoprotein with broad and potent neutralizing activity
US-9920111-B2 · Mar 20, 2018 · US
Broadly neutralizing human immunodeficiency virus type 1 (hiv-1) gp120-specific monoclonal antibody
US-2018057570-A1 · Mar 1, 2018 · US
Broadly neutralizing human immunodeficiency virus type 1 (HIV-1) GP120-specific monoclonal antibody
US-9464131-B2 · Oct 11, 2016 · US
Broadly neutralizing human immunodeficiency virus type 1 (hiv-1) gp120-specific monoclonal antibody
US-2016264649-A1 · Sep 15, 2016 · US
Major assignees
Companies most often associated with this inventor's publications.
| Assignee | Patents |
|---|---|
| Theraclone Sciences Inc | 25 |
| Scripps Research Inst | 25 |
| Int Aids Vaccine Initiative | 17 |
| Int Aids Vaccine Initiative Inc | 9 |
| Univ Cornell | 2 |
Top CPC classifications
Most common classification codes across this inventor's patents.
| CPC | Patents |
|---|---|
| C07K16/1145 | 25 |
| C07K16/114 | 25 |
| A61K39/21 | 25 |
| C07K2317/76 | 25 |
| C07K2317/565 | 25 |